As of November 10, 2026, MAIA Biotechnology, Inc. is a publicly traded company (NYSE: MAIA). The largest holder reporting an active stake on Schedule 13D is Vlad Vitoc, the executive officer and a director, at 9.66%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, December 4, 2025).
Is this your company?
About to sign with, pay or invest in MAIA Biotechnology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is MAIA Biotechnology, Inc. a real, registered company?
- MAIA Biotechnology, Inc. files with the SEC under CIK 1878313 (its SEC filings).
- Its shares are listed under the ticker MAIA on NYSE (SEC company record).
- Incorporated in Delaware; business address in Chicago, Illinois, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MAIA Biotechnology, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Solas Capital Management, LLC (filed 2026-05-15).
Who are MAIA Biotechnology, Inc.'s owners and officers?
MAIA Biotechnology, Inc.: incorporated in Delaware; business address in Chicago, Illinois; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-01-05)
- : Executive Officer, Director (Form D, 2026-01-05)
- : Executive Officer (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
- : Director (Form D, 2026-01-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Solas Capital Management, LLC | 4.9% |
| Schedule 13G, 2026-05-15 | Solas Capital Management, LLC | 7.1% |
| Schedule 13D/A, 2025-12-04 | Vlad Vitoc | 9.66% |
Questions about who owns MAIA Biotechnology, Inc.
Who owns MAIA Biotechnology, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of MAIA Biotechnology, Inc.: Vlad Vitoc (9.66%, Schedule 13D/A, filed 2025-12-04).
When did Vlad Vitoc buy into MAIA Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vlad Vitoc on this page is the Schedule 13D/A, filed 2025-12-04, reporting 9.66%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on MAIA Biotechnology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on MAIA Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MAIA Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own MAIA Biotechnology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,519,178 shares (2.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-06-02).
- , the chief executive and a director: 1,259,221 shares (2.0% of shares outstanding), 1,049,121 held directly and 210,100 indirectly (Form 4, 2026-09-15).
- , a director: 1,248,888 shares (2.0% of shares outstanding) (Form 4, 2025-12-23).
- , a director: 773,296 shares (1.3% of shares outstanding) (Form 4, 2026-09-14).
- , a director: 437,628 shares (0.71% of shares outstanding) (Form 4, 2025-12-01).
Shares outstanding: 61,750,308 as of 2026-11-09, from the company's latest SEC cover page.
How much has MAIA Biotechnology, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-01-05 | $1.51M | $2M |
| Form D, 2025-10-14 | $2.99M | $7M |
| Form D, 2025-06-11 | $695K | $8M |
| Form D, 2025-03-04 | $4.14M | $5.90M |
| Form D, 2024-11-12 | $2.44M | $15.50M |
| Form D, 2024-03-21 | $2.92M | $5.70M |
| Form D, 2023-11-29 | $4.86M | $4.86M |
Keep reading
More on MAIA Biotechnology, Inc. and the records around it.
MAIA Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Company profile and every filing Jan 2026
- Form D filing Jan 2026
- Form D filing Oct 2025
Companies that share a holder
- Solas Capital Management, LLC also filed stake reports on 5 other companies: FENNEC PHARMACEUTICALS INC. (Aug 2026), Modular Medical, Inc. (Aug 2026), SANUWAVE Health, Inc. (Aug 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/maia-biotechnology-inc